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Abstract 
Objective: Neonatal abstinence syndrome (NAS) has become an epidemic. This study assesses documented rates of 
failed newborn hearing screening (NBHS) or hearing loss (HL) diagnosis in NAS infants, and sociodemographic factors 
associated with abnormal inpatient hearing results.
Method: The 2016 HCUP/KID national database was used to identify a weighted sample of infants with failed NBHS/
HL during birth hospitalization. Independent variables included diagnoses of NAS/in-utero opioid exposure, HL risk factor 
presence, and sociodemographic data. Univariate analyses and multivariate logistic regression were used to determine 
associations between NAS and abnormal hearing assessment.
Results: NAS infants had lower odds ratio (OR) of documented failed NBHS (OR = 0.76, p < 0.05) than controls, but a 
higher rate of HL diagnosis (OR = 2.17, p < 0.01). Certain sociodemographic factors had higher OR of abnormal hearing 
results, including race (p < 0.001) (Black, OR = 1.48 and Native American, OR = 1.83), and Medicaid coverage (OR = 
1.45, p < 0.001). A lower OR of HL diagnosis was observed in females (OR = 0.84, p < 0.001) and infants with higher 
household income (OR = 0.53, p < 0.01).
Conclusion: NAS children have lower rates of inpatient documented failed NBHS and higher rates of HL diagnosis. 
The complex medical care of these infants could complicate NBHS, documentation, and subsequent follow-up. Certain 
sociodemographic factors result in a higher risk of hearing loss.
Acronyms: EHDI = Early Hearing Detection and Intervention; HCUP = Healthcare Cost and Utilization Project; HL = 
hearing loss; NAS = neonatal abstinence syndrome; KID = Kids’ Inpatient Database; NBHS = newborn hearing screening; 
OR = odds ratio 
Keywords: Neonatal abstinence syndrome, hearing loss, newborn hearing screen 
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Neonatal abstinence syndrome (NAS) is a condition of 
the newborn in which withdrawal signs and symptoms are 
displayed following exposure to an offending medication 
and/or drug of abuse (McQueen & Murphy-Oikonen, 
2016). The vast majority of cases are due to in-utero 
exposure from maternal use of opioids during pregnancy, 
and like all problems stemming from the opioid epidemic, 
the incidence of NAS has increased (Patrick et al., 
2015). This has placed strain on not only an increasing 
number of patients, families, and caretakers, but has 
also been responsible for a large economic burden within 
the healthcare system, estimated at $1.5 billion in 2012 
(Patrick et al., 2015).
There has been little to no focus on this population within 
the otolaryngology literature. As such, the needs of an 
NAS patient within this specialty are not well defined. Prior 
studies have shown NAS patients to be at risk for poor use 
of prophylactic and specialty care (Fang et al., 2015; Gill 
et al., 2007; Kivisto et al., 2014; Payot & Berner, 2000). 
Poor healthcare utilization and being lost to follow-up is a 
concern for any condition, but this is especially true with 
newborn hearing loss. There have been no reports of 
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clinically significant teratogenic effects of opioids leading to 
hearing loss in a newborn, nor has the rate of hearing loss 
in the NAS population ever been specifically assessed. 
However, there have been reports in adults of opioid use 
causing sensorineural hearing loss (Friedman et al., 2000; 
Ho et al., 2007; Rigby & Parnes, 2008; Vorasubin et al., 
2013). Infants with NAS are a significantly vulnerable 
population and deserve special attention as they may face 
barriers to hearing healthcare after birth.
The prevalence and the lifelong effects of unrecognized 
hearing impairment in a newborn have been the driving 
force to support universal newborn hearing screening. The 
Early Hearing Detection and Intervention (EHDI) guidelines 
state that children should undergo hearing screening by 
1 month of age, receive audiologic testing and diagnosis 
by 3 months if testing indicates hearing impairment, and 
have an intervention as indicated by 6 months. These 
recommendations were made by the U.S. Preventive Task 
Force and Joint Committee on Infant Hearing (JCIH) Loss 
over a decade ago and have been underscored by studies 
demonstrating improved speech and language outcomes 
in children whose care benefitted from earlier detection 
as advised by EHDI guidelines (JCIH, 2007; Kennedy 
et al., 2006; U.S. Preventive Services Task Force, 2008; 
Yoshinaga-Itano, 2017). Recently JCIH updated their 
position statement, recommending that EHDI programs 
consider a new target where hearing screening would 
occur by 1 month of age, audiologic testing and diagnosis 
by 2 months of age, and intervention as indicated by 
3 months (JCIH, 2019). Achieving this goal can prove 
difficult, especially in patient populations at risk for poor 
follow-up and healthcare use. Newborn hearing screening 
and subsequent follow-up testing can be complicated by 
many barriers, making it difficult for patients and families 
to navigate. Over 98% of children within the United States 
undergo NBHS (CDC, 2015); however, nearly 60% of 
infants fail to obtain a timely diagnosis after abnormal 
screening (CDC, n.d.). Certain sociodemographic factors, 
such as insurance status and parental education level, 
have been associated with decreased use of audiologic 
services following a failed newborn hearing screening 
(Folsom, 2000; Liu, 2008; Oghalai, 2002; Spivak, 2009). 
Communication of failed NBHS is important for continuity 
of care of timely diagnosis of infant hearing loss, however, 
many primary care providers and parents are either 
uninformed or misinformed about NBHS results (Bush, 
Alexander, et al., 2015, Bush, Hardin, et al., 2015). Birthing 
hospitals are mandated to report NBHS results to state 
Early Hearing Detection and Intervention (EHDI) agencies; 
however, the documentation and subsequent billing of 
abnormal NBHS on birth inpatient records on a local level 
is largely unknown. A disconnect between the NBHS 
results and inpatient records could influence continuity 
of care for the infant after hospital discharge. The 
relationship of NAS and infant hearing screening results 
and/or documented diagnosis of hearing loss has not been 
previously described. The primary aim of this study was 
to assess the documented rate of failed newborn hearing 
screenings and diagnoses of hearing loss in NAS patients 
during their birth hospitalizations. Furthermore, by using 
a large national inpatient admissions database, we aimed 
to assess the association of NBHS screening results and 
patient demographics and socioeconomic factors. 
Materials and Method
The study uses publicly available data that is deemed by 
the Institutional Review Board (IRB) as not involving human 
subjects and not requiring IRB review and approval. 
Study Sample
The study examines the association between NAS and 
NBHS screening results in 2016 using the Kids’ Inpatient 
Database (KID), Healthcare Cost and Utilization Project 
(HCUP), Agency for Healthcare Research and Quality. 
The database includes relevant diagnostic and procedure 
codes, as well as demographic data, for a national sample 
of pediatric inpatient hospitalizations. Pediatric inpatient 
admissions were included in the study sample if the 
admission was associated with a hospital birth, where 
NBHS is expected to be performed and where NAS could 
be detected. Admissions associated with patients at risk for 
iatrogenic NAS were excluded using methods described in 
prior studies (Patrick et al., 2012). The study also excludes 
admissions with Medicare as primary payer and where 
data on demographic variables of interest were missing.
Measures
NAS was identified using the International Classification 
of Diseases, 10th ed. [ICD-10] code P96.1. The study 
uses two measures of potential hearing loss, a failed 
NBHS or a diagnosis of hearing loss during the inpatient 
birth admission. A failed NBHS was identified using 
ICD-10 codes R94.120, R94.8, and Z01.110. Diagnosed 
hearing loss was determined using ICD-10 codes H91.90, 
H90.3, H90.41, H90.42, H90.71, H90.72, H90.6, H90.2, 
H90.11, H90.12, H90.0, H90, H90.1, H90.4, H90.5, 
H90.7, H90.8, H90.A, H90.A1, H90.A11, H90.A12, H90.
A2, H90.A21, H90.A22, H90.A3, H90.A31, H90.A32, H91, 
H91.0, H91.01, H91.02, H91.03, H91.09, H91.8, H91.8X, 
H91.8X1, H91.8X2, H91.8X3, H91.8X9, H91.9, H91.91, 
H91.92, H91.93, and H91.3. 
To control for the potential effects of known risk factors for 
hearing loss on a failed NBHS or hearing loss diagnosis, 
a variable indicating the presence of any known risk factor 
was developed. This indicator variable denotes whether or 
not sepsis, bacterial meningitis, jaundice, cytomegalovirus, 
syphilis, rubella, herpes, craniofacial anomalies, or 
persistent pulmonary hypertension were present 
diagnoses in the birth admission. ICD-10 codes were used 
to identify these diagnoses and are available upon request. 
There are other risk factors, including family history of 
hearing loss, not used to construct these variables due 
to lack of a diagnostic code to identify that the risk factor 
was present. Additional demographic measures included 
in the study include payer type, race, gender, urban/rural 
residence, and median household income, all of which are 
available in the KID. 
Statistical Approach
All statistical analyses were performed using Stata 15 
(StataCorp LL, College Station, Texas). The construction 
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of the KID and its sampling approach are described on 
the HCUP website (https://www.hcup-us.ahrq.gov/tech_
assist/sampledesign/508_compliance/index508_2018.
jsp). Statistical analyses use sampling weights to account 
for the KID’s complex design and to calculate accurate 
standard errors.  We performed descriptive univariate 
analyses to summarize the characteristics of the study 
sample, using chi-square tests to assess differences in 
demographic variables for the groups with and without a 
failed NBHS. We used multivariate logistic regression to 
test for associations between NAS diagnosis and either 
a failed NBHS or hearing loss diagnosis, controlling for 
demographic characteristics and the presence of any 
risk factors for hearing loss. We further examined, again 
using logistic regression, the association between NAS 
and, separately, each measure of hearing loss: a failed 
NBHS and a diagnosis of hearing loss. We report odds 
ratios (OR) with 95% confidence interval (CI) and a level of 
significance at alpha = 0.05.
Results
The weighted study sample included 1,113,150 
observations, of which 0.67% (n = 21,888) had a diagnosis 
of NAS. Approximately 0.71% (n = 23,185) of all infants 
had ICD-10 codes indicating either abnormal NBHS 
or diagnosis of hearing loss on inpatient birth records. 
Among those infants with NAS, 117 had a failed NBHS 
and 15 had a HL diagnosis; none had both. The incidence 
of documented failed NBHS/hearing loss diagnosis in 
the NAS cohort was 0.6% (n = 133), and not statistically 
different, compared to 0.7% (n = 23,051) in the unexposed 
cohort (p = 0.23). This is summarized in Table 1 along 
Table 1
Diagnosis of NAS and Patient Demographics and Association with Failed Newborn Hearing Screen or 
Hearing Loss Diagnosis During Birth Hospitalization (Weighted Estimates)
Note. NAS = neonatal abstinence syndrome.
†Risk=Presence of known medical risk factor for hearing loss 
with other patient-specific factors including race and sex. 
Higher rates of documentation of failed NBHS were seen 
in males (p < 0.001) and Black and Native American 
infants (p < 0.001). When assessing for an association 
between documented inpatient failed NBHS or hearing 
loss diagnosis and socioeconomic factors, statistically 
significant differences were seen based on patient 
insurance status, primary place of residence, and familial 
income levels. These findings are shown in Table 2. 
Multivariate logistic regression analyses reveal several 
findings. When a failed NBHS and hearing loss diagnosis 
are combined as the outcome variable, we identify no 
statistically significant association between NAS and 
hearing loss (OR = 0.82, p = 0.11, data not shown). This 
analysis includes a weighted sample of 22,327 infants with 
a failed NBHS, 844 with a HL diagnosis, and 12 with both. 
However, when separate regressions are performed 
for each measure, this study reveals more meaningful 
associations. Patient demographics and socioeconomic 
factors and odds of a failed NBHS (i.e. abnormal 
auditory function diagnosis) or hearing loss diagnosis are 
summarized in Tables 3 & 4, respectively. When controlling 
for confounding variables, infants with NAS had a lower 
odds ratio of documentation of abnormal NBHS (OR = 
0.76, p < 0.05) compared with non-NAS infants. There 
is also a statistically significant difference in the odds of 
 
Abnormal Auditory Function Diagnosis or Hearing Loss Diagnosis 
  No Yes  
  n % n % p-value 
NA
S No 3,234,872 99.3% 23,051 0.7% 0.2329 Yes 21,754 99.4% 133 0.6% 
Ri
sk
 †  No 3,214,278 99.3% 22,943 0.7% 
< 0.05 Yes 42,348 99.4% 241 0.6% 
Se
x 
Male 1,665,967 99.2% 12,857 0.8% 
< 0.001 
Female 1,590,659 99.4% 10,328 0.6% 
Ra
ce
 
White 1,693,045 99.4% 10,916 0.6% 
< 0.001 
Black 466,282 99.1% 4,410 0.9% 
Hispanic 655,020 99.2% 4,968 0.8% 
Asian or Pacific 
Islander 201,572 99.5% 1,044 0.5% 
Native 
American 22,442 98.7% 291 1.3% 
Other 218,262 99.3% 1,553 0.7% 
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Table 2
Socioeconomic Characteristics and Association with Failed Newborn Hearing Screen or Hearing Loss 
Diagnosis During Birth Hospitalization (Weighted Estimates)
†Patient Geography: Central metro = county population > 1 million; Fringe metro = co. pop. > 1 million; 
Mid-metro = co. pop. 250,000–999,999; Small-metro = co. pop. 50,000–249,999; Micropolitan = co. pop. 
49,999–10,000; Not metro- or micropolitan = co. pop. < 10,000.
    
Abnormal Auditory Function Diagnosis or Hearing Loss Diagnosis 
  
  No Yes  
  n % n % p-value 
Pa
ye
r T
yp
e 
Medicaid 1,518,324 99.2% 12,204 0.8% 
< 0.001 
Private Insurance 1,499,297 99.4% 9,325 0.6% 
Self-Pay 146,617 99.3% 1,083 0.7% 
No Charge 1,590 98.6% 23 1.4% 
Other 90,796 99.4% 548 0.6% 
Pa
tie
nt
 G
eo
gr
ap
hy
 †  Central metro 1,123,029 99.4% 7,017 0.6% 
< 0.001 
Fringe metro 781,982 99.4% 5,110 0.6% 
Mid-metro 643,885 99.2% 5,149 0.8% 
Small metro 270,852 99.2% 2,274 0.8% 
Micropolitan 262,985 99.1% 2,273 0.9% 
Not metro- or 
micropolitan 173,890 99.2% 1,359 
0.8% 
In
co
m
e 
Qu
ar
til
e 1st (< $25,000) 953,931 99.2% 7,640 0.8% 
< 0.001 
2nd ($25,000–
$34,999) 803,257 99.3% 5,958 
0.7% 
3rd ($35,000–
$44,999) 797,211 99.3% 5,719 
0.7% 
4th (> $44,999) 702,226 99.5% 3,866 0.5% 
 
 
diagnosed hearing loss between NAS infants and non-
NAS infants (OR = 2.17, p < 0.01). Sociodemographic 
factors with higher odds of abnormal NBHS results 
included Medicaid insurance status (OR = 1.27, p < 0.001), 
Black race (OR = 1.48, p < 0.001), Native American race 
(OR = 1.83, p < 0.01), and smaller metropolitan residence 
(OR = 1.33–1.44, p < 0.05). Factors with lower odds 
ratio of abnormal NBHS results included female gender 
(OR = 0.85, p < 0.001) and presence of a medical risk 
factor for hearing loss (OR = 0.69, p < 0.001). There 
are no observed associations between family income 
and an abnormal NBHS. Sociodemographic factors with 
higher odds ratio of diagnosis of hearing loss during birth 
admission records included Medicaid as the primary 
payer (OR = 1.45, p < 0.001) and presence of a medical 
risk factor for hearing loss (OR = 3.02, p < 0.001). Other 
factors with lower odds ratio of diagnosis of hearing loss 
were female gender (OR = 0.84, p < 0.001) and family 
income over $45,000 (OR = 0.53, p < 0.01).  
Discussion
The most recently available data from the Centers for 
Disease Control and Prevention estimates a rate of failed 
newborn hearing screen at 1.7% with the prevalence of 
newborn hearing loss at 1.7 per 1,000 infants screened 
(CDC, 2018b). These data are reported to the CDC from 
each state EHDI program as collected from birthing 
hospitals. These data are collected from hospitals 
outside the medical record through reporting systems 
that are distinct from hospital records and billing. From 
an epidemiological standpoint, it is valuable to have data 
on the incidence and prevalence of infant hearing loss 
on a national level; however, these data are detached 
from the medical record of infants, which may limit 
progress in large scale research regarding other medical 
or sociodemographic factors associated with abnormal 
NBHS and infant hearing loss, when those factors are not 
captured in the EHDI program. With current EHDI data, 
it is impossible to investigate for links between medical 
conditions such as NAS and infant hearing loss, thus, 
other research tools and databases must be used. Unlike 
hospital EHDI data, there is no mandate or requirement of 
reporting abnormal NBHS results or hearing loss diagnosis 
in administrative records and it is possible that diagnoses 
related to abnormal NBHS and infant hearing loss may be 
underreported or may go unreported. 
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Table 4
Logistic Regression Analysis: Likelihood an Infant Failed Their Hearing Screen or was Given a Diagnosis 
of Hearing Loss Based on Socioeconomic Characteristics
Note. N = 951,437. †Patient Geography: Central metro = county population > 1 million; Fringe metro = 
co. pop. > 1 million; Mid-metro = co. pop. 250,000–999,999; Small-metro = co. pop. 50,000–249,999; 
Micropolitan = co. pop. 10,000–49,999; Not metro- or micropolitan = co. pop. < 10,000.
‡Excluded from analysis due to small sample size and perfect failure prediction.
Logistic Regression Analysis, Likelihood of Abnormal Hearing Assessment 
 
 Abnormal Auditory Function Hearing Loss Diagnosis 
  Odds Ratio (95% CI, p) Odds Ratio (95% CI, p) 
Pa
ye
r T
yp
e 
Private 1.00 1.00 
Medicaid 1.13 (1.02–1.25, < 0.05) 1.45 (1.19–1.77, < 0.001) 
Self-Pay 1.10 (0.91–1.33, 0.34) 1.21 (0.80–1.81, 0.36) 
No Charge 2.24 (0.72–6.85, 0.16) n/a‡ 
Other 0.87 (0.66–1.16, 0.35) 1.41 (0.66–3.01, 0.37) 
Pa
tie
nt
 G
eo
gr
ap
hy
†  
Central metro 1.00 1.00 
Fringe metro 1.10 (0.89–1.35, 0.37) 1.59 (0.87–2.93, 0.14) 
Metro of 250,000–
999,999 1.33 (1.03–1.71, < 0.05) 0.58 (0.32–1.07, 0.08) 
Metro of 50,000–
249,999 1.39 (1.04–1.86, < 0.05) 0.93 (0.40–2.15, 0.87) 
Micropolitan 1.44 (1.08–1.93, < 0.05) 0.79 (0.40–1.58, 0.51) 
Not metro- or 
micropolitan 1.26 (0.95–1.68, 0.11) 1.53 (0.59–4.0, 0.385) 
In
co
m
e 
Q
ua
rt
ile
 
1st (< $25,000) 1.00 1.00 
2nd ($25,000–$34,999) 1.0 (0.88–1.13, 0.95) 0.83 (0.56–1.25, 0.38) 
3rd ($35,000–$44,999) 1.03 (0.90–1.18, 0.68) 0.96 (0.72–1.29, 0.0.80) 
4th ($45,000 and 
above) 0.89 (0.75–1.04, 0.15) 0.53 (0.34–0.81, < 0.01) 
 
Table 3
Logistic Regression Analysis: Likelihood an Infant Failed Their Hearing Screen or was Given a 
Diagnosis of Hearing Loss Based on Patient-Specific Factors
Note. NAS = neonatal abstinence syndrome. N = 951,437 
Risk = Presence of known medical risk factor for hearing loss.
 Logistic Regression Analysis, Likelihood of Abnormal Hearing Assessment 
  Abnormal Auditory 
Function Hearing Loss Diagnosis 
  Odds Ratio (95% CI, p) Odds Ratio (95% CI, p) 
 NAS 0.76 (0.58–0.98, < 0.05) 2.17 (1.23–3.85, < 0.01) 
 Risk† 0.69 (0.58–0.82, < 0.001) 3.02 (1.85–4.95, < 0.001) 
 Female 0.84 (0.79–0.90, < 0.001) 0.84 (0.73–0.96, 0.01) 
R
ac
e 
White 1.00 1.00 
Black 1.48 (1.30–1.69, < 0.001) 0.77 (0.48–1.24, 0.29) 
Hispanic 1.18 (0.99–1.41, 0.06) 1.14 (0.73–1.79, 0.56) 
Asian or Pacific 
Islander 0.90 (0.74–1.10, 0.31) 0.98 (0.70–1.39, 0.92) 
Native American 1.83 (1.19–2.81, < 0.01) 1.94 (0.93–4.03, 0.08) 
Other 1.19 (0.94–1.49, 0.138) 0.68 (0.36–1.26, 0.22) 
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Our data are discordant with CDC findings, yielding a 
lower overall rate of failed hearing screen or hearing 
loss diagnosis of 0.71% in this inpatient sample of 
birth hospitalizations. This study found, using uni- and 
multivariate analysis, that infants with NAS have a lower 
odds ratio of reported abnormal NBHS results on inpatient 
discharge records than non-NAS infants. These findings 
could be due, simply, to an actually lower incidence 
of abnormal NBHS in NAS infants. There is no other 
evidence that would suggest that neonatal substance 
exposure is protective against hearing loss. 
Conversely, we hypothesize that abnormal NBHS is 
underreported in the inpatient records and hospital billing 
of NAS infants which could account for the lower odds 
ratio found in this data. The complexity of medical care 
and multi-disciplinary discharge follow-up of NAS infants 
could influence the reporting of abnormal NBHS on 
inpatient hospital records. If proven true, this hypothesis is 
significant as it indicates that complex medical conditions 
in infants, such as NAS, could negatively influence the 
reporting of NBHS results. This could lead to delays in 
the diagnosis and treatment of hearing loss within the 
local medical community if NAS is indeed a risk factor 
for hearing loss. This hypothesis is further supported by 
this data which found a significantly lower odds ratio of 
documented abnormal NBHS in infants with known risk 
factors for hearing loss. These factors include complex 
medical conditions such as perinatal maternal infections, 
craniofacial abnormalities, ototoxic drug exposure, NICU 
admission, prematurity, and hyperbilirubinemia. These 
complex medical conditions along with other conditions 
in the infant would be prioritized in the inpatient and 
early outpatient care of infants which could influence 
the reporting of NBHS results, along with other relevant 
clinical findings. This study also finds a difference in 
the actual diagnosis of hearing loss of NAS-infants and 
non-NAS infants based on inpatient data. Although the 
overwhelming majority of infants who are diagnosed 
with hearing loss receive that diagnosis after multiple 
audiological evaluations on an outpatient basis, this study 
suggests that infants with NAS and congenital hearing loss 
may receive definitive audiological evaluation in addition 
to NBHS due to their prolonged inpatient stays in the 
hospital. Although this study does not test for the causal 
relationship between NAS and hearing loss diagnosis, it 
is the first to identify a relationship between the two in an 
infant population. 
Although few cases have been reported in the adult 
literature of hearing loss from opioid use, there is not 
strong evidence to suggest ototoxicity with in-utero opiate 
exposure. Our findings, based on birth hospitalization data, 
found there was no significant difference in hearing loss 
incidence between the exposed and unexposed cohorts. 
More research is needed to assess the relationship 
between NAS and infant hearing loss as the complex care 
and increased length of stay required by these patients 
can make identification of hearing loss a difficult task. 
Subsequent work should be completed to follow these 
patients into childhood to ensure longevity of hearing 
health or recognize later needs, as well as improve 
detection of delayed onset or progressive hearing loss 
not observable in the birth admission. It is also important 
to stress the need for thorough discharge planning for 
these patients and confirmation of audiologic follow-up in 
the event of a failed NBHS given their risk of poor use of 
prophylactic and specialty healthcare services (Fang et al., 
2015; Gill et al., 2007; Kivisto et al., 2014).
In this study, we also assessed patient and socioeconomic 
factors associated with documented abnormal NBHS/
infant hearing loss. In doing so, increased rates of failed 
hearing screens and hearing loss diagnoses were noted in 
vulnerable patient populations. Medicaid insurance status 
had higher odds of abnormal hearing assessments and 
diagnoses compared to patients with private insurance. 
Place of residence was also associated with differences 
in hearing assessment. Patients from outside a central 
metropolitan area were at increased odds of failed 
NBHS. The greatest likelihood was seen in micropolitan 
(county population 10,000-49,999), OR = 1.44. Compared 
to the lowest earning families, patients whose family 
incomes were in the 4th quartile had decreased odds 
ratios of HL, OR = 0.53 (p < 0.01). By using data from 
the National Health Interview Survey, Boss et al., 2011 
also described increased rates of hearing loss in children 
of lower socioeconomic status. Increased rates of failed 
NBHS or HL diagnoses from national inpatient data in 
children covered by Medicaid, and in those from smaller 
communities are novel findings not yet reported in the 
literature. The possibility of failed NBHS or HL diagnoses 
is concerning given these are populations already at-
risk for worse audiologic follow-up or decreased access 
to care following a failed NBHS. Prior studies with small 
samples have shown that loss to follow up and decreased 
care access are common for children from rural areas or 
outside a central metropolitan area, who are uninsured or 
covered by public insurance, and come from families with 
lower incomes and lower parental education levels (Bush 
et al., 2014; Liu et al., 2008; Oghalai et al., 2002; Ravi et 
al., 2016; Zeitlin et al., 2017). Individuals who identified 
as Black, OR =1.48 (p < 0.001) or Native American, OR = 
1.24 (p = 0.02), were more likely to have abnormal hearing 
assessments. Unfortunately, racial and ethnic minorities 
have been noted to be at higher risk for loss to follow-up 
after a failed NBHS (CDC, 2018a; Liu et al., 2008; Zeitlin 
et al., 2017). This again highlights patient populations not 
only at risk for increased rates of hearing loss but also 
worse use of subsequent care.
This study is limited most notably by its retrospective 
nature and reliance on administrative data, which may 
not document all clinically-relevant information. Although 
98% of newborns received hearing screening in 2015 
(CDC, 2015), it must be noted that differing techniques of 
screening and reporting mechanisms are used throughout 
the country. As EHDI and KID data rely on reporting from 
national samples, testing and diagnostic homogeneity 
cannot be assumed for this study. Likewise, NAS is 
a clinical diagnosis made based on a constellation of 
signs and symptoms, and there is no uniform evaluation 
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mechanism to make this diagnosis (McQueen & Oikonen, 
2016). Finally, our study uses imprecise measures of 
the outcome of an abnormal NBHS. We rely on ICD-10 
codes for “abnormal auditory function” that may not be 
consistently coded in billing programs when an infant fails 
their screen. 
Conclusion
NAS children have a lower rate of inpatient documented 
failed NBHS and a higher odds of HL diagnosis during 
the birth admission. The complex medical care of these 
infants could complicate NBHS and subsequent follow-
up. Certain sociodemographic factors including some 
racial and ethnic minorities, lower income level, residence 
outside a metropolitan center, and Medicaid insurance 
are associated with higher risk of hearing loss. Further 
research is needed to assess hearing screening and 
diagnoses of hearing loss in vulnerable populations such 
as NAS infants.
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